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Abstract 
The membrane pore-forming activities of the antimicrobial peptide GWH1 have been 
evaluated in combination with the CXCR4-binding properties of the peptide T22, in self-
assembling protein nanoparticles with high clinical potential. The resulting materials, of 
25 nm in size and with regular morphologies, show a dramatically improved cell 
penetrability into CXCR4+ cells (more than 10-fold) and enhanced endosomal escape 
(the lysosomal degradation dropping from 90 % to 50 %), when compared with 
equivalent protein nanoparticles lacking GWH1. These data reveal that GWH1 retains 
its potent membrane activity in form of nanostructured protein complexes. On the other 
hand, the specificity of T22 in the CXCR4 receptor binding is subsequently minimized 
but, unexpectedly, not abolished by the presence of the antimicrobial peptide. The 
functional combination T22-GWH1 results in 30 % of the nanoparticles entering cells via 
CXCR4 while also exploiting pore-based uptake. Such functional materials are capable 
to selectively deliver highly potent cytotoxic drugs upon chemical conjugation, promoting 
CXCR4-dependent cell death. These data support the further development of GWH1-
empowered cell-targeted proteins as nanoscale drug carriers for precision medicines. 
This is a very promising approach to overcome lysosomal degradation of protein 
nanostructured materials with therapeutic value.  
  
Introduction 
Cell-targeted drug delivery requires appropriate nanoscale vehicles (usually 
nanoparticles) for the generation of nanoconjugates [1]. These carriers have to be 
functionalized with appropriate ligands (usually peptides or proteins) that selectively bind 
to cell surface receptors overexpressed in target cells [2]. Selective delivery is specially 
desired in oncology, in which conventional therapy is majorly based on the systemic 
administration of untargeted chemotherapeutic drugs, associated to severe life-
threatening side toxicity [3-7]. A nanoscale size of the conjugate, ranging from 10 to 100 
nm, allows exploiting the enhanced permeability and retention (EPR) effect (based on 
the higher blood vessel permeability in tumoral tissues) while avoiding renal clearance 
(with a cut-of around 6-8 nm) and undesired aggregation in lung capillaries [8]. A diversity 
of materials is explored as nanoscale drug carriers including polymers, ceramics, metals 
and carbon nanotubes. The xenobiotic nature and potential toxicity of most of them pose 
severe concerns about their biosafety, at both individual and environmental levels [1, 9-
18]. Contrarily, self-assembling proteins are promising, fully biocompatible 
nanostructured materials for drug delivery [19, 20]. The development of nanosized 
protein materials is strongly pusher by emerging nanobiotechnologies [20-24], that allow 
the engineering of proteins to confer self-assembling at the nanoscale. Being functionally 
versatile, proteins and protein materials can perform complex activities such as precise 
cell targeting, by the incorporation of peptide ligands in modular polypeptides, that act 
as building blocks of nanoscale entities [25]. In this context, T22 is a highly selective 
cationic ligand of the cytokine receptor CXCR4, that is overexpressed in about 20 human 
neoplasias and that correlates with aggressiveness and metastasis [26-32]. T22 
promotes the endosomal-mediated internalization of non-amyloidal, self-assembling 
protein nanoparticles (formed by the T22-GFP-H6 fusion protein as building block), that 
result in the range size of 12 and 20 nm [33]. Selective T22-mediated binding and 
internalization result in a high level of specificity both in vitro and in vivo [34-36], and in 
an optimal biodistribution of the material in colorectal cancer animal models, when 
systemically administered [37]. In this context, T22-GFP-H6 nanoparticles have been 
recently used as potent nanocarriers of conventional antitumoral drugs [38], and closely 
related protein nanoparticles as vehicles for specific cytotoxic protein delivery in different 
cancer animal models [39, 40], both approaches with high therapeutic impact.  
In protein-based nanoparticles, functional recruitment by protein fusion technologies [40-
42] might be useful to enhance the penetrability of this construct (and similar nanoscale 
protein materials), which is now moderate, in order to improve its applicability as drug 
carrier. In this regard, poor endosomal escape and consequent lysosomal degradation 
may be a critical bottleneck for T22-GFP-H6 to efficiently deliver cytotoxic drugs into the 
cytoplasm, as generically observed for proteins and confirmed in our laboratory for 
CXCR4-targeted constructs (U. Unzueta, unpublished data). Since self-assembling 
proteins are highly versatile materials, we have here studied the combined activity of T22 
and that of a potent pore-forming protein, the antimicrobial peptide (AMP) GWH1, 
simultaneously displayed on the surface of protein nanoparticles. Although highly 
promising in nanomedical applications, the combination of cell-targeting peptides and 
enhancers of cell penetrability has been so far poorly studied, while it might offer a way 
to overcome lysosomal degradation and limited functionality in the target cell. The data 
presented here demonstrate that GWH1 shows potent endosomolytic activity that 
increases transfection efficiently of functionalized protein nanoparticles into the 
cytoplasm. Despite this fact, the CXCR4 binding specificity is conserved, although 
reduced, in these materials. The functional combination provided by the peptide pair is 
then a promising approach to enhance the performance of smart drug nanocarriers 
based on functional peptides. 
Materials and methods 
Nanoparticle production and characterization 
Self-assembling modular proteins T22-GFP-H6 [34], T22-GWH1-GFP-H6 [42] and 
GWH1-GFP-H6 [43] (Figure 1 A) have been described elsewhere. T22 is a powerful 
ligand of the cell surface cytokine receptor CXCR4 [34], overexpressed in more than 20 
aggressive human neoplasias [28, 30, 44] and that acts as a highly convenient target for 
the precision delivery of antitumoral and antimetastatic drugs [38-40]. T22 mediates the 
endosomal internalization of fusion proteins that contain the peptide, in CXCR4+ cells, 
both in vitro and in vivo [34, 36]. These gene fusions were expressed from the plasmid 
pET22b in Escherichia coli Origami B (BL21, OmpT-, Lon-, TrxB-, Gor-, Novagen) under 
standard conditions [37]. Cells were disrupted in a French Press (Thermo FA-078A) at 
1200 psi to obtain the soluble fraction. Protein purification was carried out through the 
His-tag by Immobilized Metal Affinity Chromatography (IMAC) using a HiTrap Chelating 
HP 1 ml column (GE Healthcare) with an AKTA purifier FPLC (GE Healthcare) [45]. 
Proteins were finally dialyzed against sodium bicarbonate buffer with salt (166 mM 
NaHCO3 pH 8 + 333 mM NaCl). Protein purity and integrity were checked by mass 
spectrometry (MALDI-TOF) and protein amounts by the Bradford assay.  
 
Morphometric (size and shape) and ultrastructural characterization 
The volume size distribution of nanoparticles was determined by dynamic light scattering 
(DLS) at 633 nm (Zetasizer Nano ZS, Malvern Instruments Limited, Malvern). The 
surface charge of proteins was assessed by zeta potential (Zp). Zp was measured at 
25 °C and 633 nm, and DTS1070-folded capillary cell was used as sample container 
(Zetasizer Nano ZS, Malvern Instruments Limited). For quantitative analyses, three 
replicas of each sample were analyzed and the error in the measurements were 
estimated. Shape of nanoparticles was evaluated with a Field emission scanning 
electron microscopy (FESEM) Zeiss Merlin (Zeiss) equipped with a high resolution in-
lens secondary electron detector and operating at 1 kV. To estimate the molecular mass 
of the purified nanoparticles size exclusion chromatography (SEC) was performed on a 
Superdex 200 10/300 column (GE Healthcare). The column was previously calibrated 
with molecular-mass standards (GE Healthcare) and injected protein nanoparticles (250 
µl each) were eluted with a sodium bicarbonate buffer.  
 
Membrane preparation and Circular dichroism (CD) 
Multilamellar vesicles were prepared by evaporating, under a stream of nitrogen, 
chloroform:methanol (2:1 v/v) from a solution of pure egg phosphatidyl choline (EPC) 
(Sigma Aldrich). The dry lipid was resuspended in buffer at 1 mg/ml by repeating six 
consecutive cycles of heating for 2 min at 21 ºC (a temperature above the phospholipid 
Tc) and vortexing for 1 min. In these conditions, EPC self-aggregates into multilamellar 
vesicles (MLVs) [46]. Small unilamellar vesicles (SUVs) were prepared using a high 
intensity sonicator Branson sonifier 450, with 3 mm-diameter titanium probe. 1 ml of 
MLVs dispersion containing 4 mg/ml of EPC maintained on ice was sonicated for six 
cycles of 20 sec, each one with 50% pulses (0.5 sec on and 0.5 sec off) The last sample 
was centrifuged at 15000 g x 15 min to discard big aggregates and titanium particles. 
 
Far-UV CD was measured at 25ºC in a Jasco J-715 spectropolarimeter to assess 
secondary structure information. The concentration of T22-GFP-H6 and T22-GWH1-
GFP-H6 was adjusted to 0.2 mg/ml in a buffer solution of 166 mM carbonate-bicarbonate 
at pH 8 and 333 mM NaCl. The protein spectrum was measured in the absence or the 
presence of small unillamellar vesicles (SUVs) (phosphatidylcholine at 0.5 and 1 mg/ml ). 
Samples were analysed with a 1 mm path length cuvette.CD spectra were obtained over 
a wavelength range of 190-240 nm at a scan rate of 50 nm/min a response of 1 sec and 
a bandwidth of 1 nm. Six scans were accumulated.  
 
Cell culture and cell viability assay  
Cervical and colorectal cancer cell lines were used to study the performance of 
recombinant proteins in vitro ( CXCR4+ HeLa, CXCR4+ SW1417 and CXCR4- SW1417 
cells). HeLa cells were cultured in MEM Alpha (Minimum Essen
supplemented with 10 % fetal calf serum (Gibco) at 37 °C and 5 % CO2 in a humidified 
atmosphere whereas SW1417 cells in Dulbecco's Modified Eagle's Medium (Gibco). To 
explore internalization and CXCR4 specific uptake of proteins, culture media was 
exchanged for serum-free Optipro medium (Gibco) supplemented with L-glutamine prior 
to the addition of nanoparticles. T22-GWH1-GFP-H6 and control T22-GFP-H6 and 
GWH1-GFP-H6 nanoparticles were added at 25 nM during 2 h in HeLa and SW1417 
cells. Specific internalization through CXCR4 receptor was proved adding 1 h prior 
protein incubation a specific antagonist of CXCR4, AMD3100 at a ratio of 1:10. The 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was used to determine the 
cytotoxicity of protein nanoparticles. For that, HeLa cells were plated in opaque-walled 
96-well plates at 3,500 cells/well in DMEM supplemented with 10 % fetal calf serum for 
24 h at 37 ºC until reaching 70 % confluence. Then, cells were incubated in presence of 
2, 4, 8, 12 and 24 µM nanoparticles during 48 h at 37°C. Subsequently, 100 µl of the 
single reagent (CellTiter-Glo® Reagent) was added directly to cultured cells and the 
plates were measured in the Multilabel Plater Reader VICTOR3 (PerkinElmer). 
 
Internalization and endosomal degradation assays 
To determine the threshold concentration for endosomal membrane destabilization, T22-
GWH1-GFP-H6 and control T22-GFP-H6 and GWH1-GFP-H6 nanoparticles were added 
at 0.5, 1, 2, 3 and 4 M and left for 24h. To analyze endosomal escape of proteins, HeLa 
induces vesicular rupture through protonation, in the acidic environment of late 
endosomes and lysosomes [47, 48] Since chloroquine allows endosomal release and 
prevents lysosomal proteolysis [49], the increase in the intracellular material upon 
chloroquine addition is observed as indicative of the extent of lysosomal degradation of 
internalized protein in absence of the drug.  
 
The uptake kinetics were recorded by exposing cells to nanoparticles at 1 and 4 
2, 5.5, 11, 16, 21 and 24 h prior to fluorescence measurement. Again, chloroquine was 
used for the determination of endosomal escape. Internalization was analyzed by 
detaching the cells with 1 mg/ml trypsin-EDTA (Gibco®) for 15 min, in a protocol 
specifically designed to remove externally attached protein [50]. The samples were 
analyzed by a FACS-Canto system (Becton Dickinson) using a 15 mW air-cooled argon 
ion laser at 488 nm excitation. All experiments were performed in duplicate. 
Fluorescence data recorded by cytometry were corrected by the specific fluorescence of 
the protein to render comparative units in terms of protein amount. The specific 
fluorescence was previously determined by a Varian Cary Eclipse fluorescence 
spectrophotometer (Agilent Technologies) at 523 nm using an excitation wavelength of 
488 nm.  
 
Confocal laser scanning microscopy 
For confocal microscopy, HeLa cells were grown on Mat-Tek plates (MatTek 
Corporation). Upon exposure to nanoparticles at 4 µM for 24 h, cell nuclei were labelled 
CellMaskTM Deep Red (ThermoFischer) for 10 min at room temperature. Cells were then 
washed in PBS (Sigma-Aldrich Chemie GmbH). Live cells were recorded with a TCS-
SP5 confocal laser scanning microscope (Leica Microsystems) using 63x (1.4 NA) oil 
immersion objective lenses. Hoechst 33342 labelled DNA was excited with a blue diode 
(405 nm) and detected in the 415-460 nm range. GFP-proteins were excited with an Ar 
laser (488 nm) and detected in the 525-545 nm range. CellMask was excited with a HeNe 
laser (633 nm) and detected in the 650-775 nm range. The confocal pinhole was set to 
1 Airy unit and z-stacks acquisition intervals were selected to satisfy Nyquist sampling 
criteria. Three-dimensional images were obtained using the Surpass Module in Imaris 
X64 v.7.2.1. software (Bitplane). 
 
Synthesis and characterization of the T22-GWH1-GFP-H6-Auristatin nanoconjugate  
The T22-GWH1-GFP-H6-Auristatine nanoconjugate (T22-GWH1-GFP-H6-A) was 
synthesized by covalent binding of the protein nanoparticle and Auristatin. The final 
conjugate was obtained by reacting maleimide groups of Auristatin with primary amines 
of nanoparticles (like lysine and arginine sidechains) favoured at pH = 8. The quality 
analysis of the conjugation was performed by MALDI-TOF spectra. The molecular mass 
of the T22-GWH1-GFP-H6-A carrying from 7 to 14 auristatin molecules (911 Da each) 
was identified by mass spectrometry. Next, we studied T22-GWH1-GFP-H6-A cytotoxic 
activity measuring cell viability and using the CellTiter-Glo® Luminescent Cell Viability 
Assay (Promega), following manufacturer recommendations. To that purpose, we 
exposed CXCR4+ HeLa cells to T22-GWH1-GFP-H6-
compared to equimolecular concentrations of T22-GFP-H6-A or T22-GWH1-GFP-H6.  
Statistics 
All the experiments were performed in triplicate. One-
least significant difference (LSD) method was used for multiple comparisons. Pairwise 
comparisons were performed using Student-t tests. Statistical differences (indicated as 
* in the Figures) were assumed at p<0.01. Microsoft Excel was used for all statistical 
analyses. 
  
Results 
T22-GWH1-GFP-H6 (Figure 1A) contains the AMP GWH1 inserted as an additional 
module between the N-terminal CXCR4 ligand T22, and the core GFP. This protein, as 
well as the related constructs T22-GFP-H6 and GWH1-GFP-H6 (Figure 1A), form regular 
nanoparticles with a toroid-like morphology, because of the cationic character of the N-
terminal region [51]. These materials show distinguishable Z potential values and 
nanoscale sizes (Figure 1A, B). In particular, T22-GWH1-GFP-H6 organizes as 
structures sizing 25 nm in average, being larger than the parental T22-GFP-H6 (12 nm) 
and smaller than the shorter GWH1-GFP-H6 (47 nm). SEC analysis of the three 
materials revealed different elution peaks, from which we estimated the structural 
composition of the particles in 31, 11 and 45 monomers respectively. The value for T22-
GFP-H6 (formed by 11 building blocks), fits reasonably well with a previous in silico 
modelling of the oligomeric nanoparticle, that predicted the material being composed by 
10 regularly accommodated GFP monomers [37]. 
 
We were interested in knowing if GWH1, a pore-forming peptide, might enhance the 
penetrability of the protein construct mediated by the specific interaction between T22 
and CXCR4, upon endosomal membrane destabilization. GWH1 exerts its cytolytic 
activity by folding into an amphipathic helix upon selective binding and insertion into the 
target membrane. In order to investigate whether the addition of the T22 moiety and the 
nanoparticulated form itself might affect the -helical structures, we 
measured the peptide conformation by circular dichroism (CD) in the absence or the 
presence of small unillamellar vesicles (SUVs). The T22-GWH1-GFP-H6-spectrum in 
the absence of SUVs shows -strand pattern corresponding to 
the expected beta-barrel structure of the GFP (Figure 2A), with a minimum around 218 
nm [52]. By contrast, when these nanoparticles interact with SUVs a qualitative change 
is observed in the DC spectrum in which the minimum moved to 222 nm (Figure 2A) 
corresponding to the appearance of novel helical conformation. Interestingly T22-GFP-
H6 did not exhibit this qualitative change in CD spectrum as it interacted with SUVs 
(Figure 2A, bottom).   
 
AMPs, as effective self-defence tools, exhibit a threshold concentration (called the lethal 
concentration) for their membrane activity on eukaryotic cells, below which no effect is 
observed [53]. This security level allows the antimicrobial activity at low concentrations, 
without harming own body cells. Since it had been previously described that GWH1 
exhibits cytotoxic effects over cancer cells with a reported threshold ranging from 20 µM 
to 250 µM, we first determined the intrinsic cytotoxicity of T22-GWH1-GFP-H6 over 
CXCR4+ HeLa cells. As observed (Figure 2B), T22-GWH1-GFP-H6 nanoparticles 
showed a dose-dependent cytotoxicity with a significant lethal concentration lower than 
the predicted for the GWH1 peptide alone. This cell killing effect, when properly targeted 
to tumoral tissues, has proved to be exploitable to design antitumoral drugs [42]. Under 
8 µM, no cytotoxicity was observed in HeLa cells upon exposure to T22-GWH1-GFP-H6 
nanoparticles, and further analysis of cell penetrability and specificity were performed in 
a safe margin, up to 4 µM.  
 
 
 
Figure 1. Features of GWH1-carrying nanoparticles. A. Modular organization of the set 
of protein building blocks used in this study. All the shown polypeptides self-assemble 
as fluorescent nanoparticles. Hydrodynamic size (in nm, measured by DLS) and 
polydispersion index (pdI) are shown at the bottom of each cartoon and Z-potential (Zp) 
of the nanoparticles (in mV) are also indicated. B. FESEM examination and size-
exclusion chromatograms of purified nanoparticles monitored by UV detector at 280 nm. 
Bars indicate 50 nm, and all images have the same magnification. EV indicates the 
elution volume.  
 
  
Then, endosomal escape promoted by GWH1 was evaluated by comparison between 
T22-GWH1-GFP-H6 and its parental T22-GFP-H6. As observed (Figure 3A), over 1.5 
µM, T22-GWH1-GFP-H6 is dramatically more efficient than T22-GFP-H6 in escaping the 
endosome, suggesting a threshold concentration for endosomal membrane 
destabilization. This action cannot be performed by the control nanoparticle GWH1-GFP-
H6, which lacks the cell surface ligand (T22) for internalization. Such endosomal escape 
protects the 40 % of the internalized protein nanoparticles from lysosomal degradation 
(Figure 3B), that is responsible for the destruction of most T22-GFP-H6. Interestingly, 
the presence of GWH1 impairs, contrarily, the CXCR4-dependence in the uptake of the 
protein materials (Figure 3C) but it does not abort it. Less than 2 % of T22-GFP-H6 enters 
target cells in the presence of the CXCR4 antagonist AMD3100, while almost 70 % of 
T22-GWH1-GFP-H6 penetrates HeLa cells under the same conditions (Figure 3C).  
 
 
Figure 2. Interaction of GWH1-containing nanoparticles with cell membranes. A. T22-
GWH1-GFP-H6 and T22-GFP-H6 CD spectra at wavelength range of 200 240 nm. In 
the absence of SUVs, both spectra of proteins indicate the occurrence of -sheet 
conformation. The CD spectra of T22-GWH1-GFP-H6, in presence of membranes, 
shows the appearance of the helical content. B. Intrinsic cytotoxicity on HeLa cells 
imposed by the AMP GWH1. Cells were incubated in presence of 2, 4, 8, 12 and 24 µM 
of protein assembled as nanoparticles during 48 h. T22-GFP-H6 does not show any 
biological effect at these doses. A threshold for GWH1 toxicity is shown  
 
 
 
Figure 3. Cell penetration and endosomal escape of GWH1-containing nanoparticles. A. 
Cell internalization of GWH1-empowered nanoparticles measured through intracellular 
fluorescence, after a harsh trypsin treatment to remove external material. A threshold for 
the endosomal escape properties is shown at 1.5 µM. FU are fluorescence units. B. 
Fraction of internalized protein degraded in the endosomes, as measured by chloroquine 
addition. Cells were incubated in the absence and in the pre
Specificity 
of CXCR4-mediated internalization of nanoparticles added at 25 nM visualized through 
the fraction of protein internalization inhibited by the CXCR4 antagonist, AMD3100 [54-
56], incubated 1 h prior to protein treatment at a ratio of 1:10. * indicates significant 
differences between T22-GWH1-GFP-H6 data and that of the other proteins .  
 
 
 
 
 
Figure 4. Dynamics of cell penetration of GWH1-containing nanoparticles. A. Kinetics of 
cell penetration of GWH1-empowered nanoparticles. Relative amounts of intracellular 
nanoparticles penetrating HeLa cells at different times after exposure (at 2 different 
concentrations). B. Endosomal release of T22-GWH1-GFP-H6 under the same 
conditions. * indicates significant differences between T22-GWH1-GFP-H6 data and that 
of the other proteins.  
 
 
 
In accordance to the obtained results, at a concentration (1 µM) in which GWH1 does 
not promote endosomal escape, the cell uptake of T22-GWH1-GFP-H6 is slightly higher 
than that of the parental T22-GFP-H6 (Figure 4A). The uptake slows down at about 5 h, 
reaching a steady constant intracellular concentration during 24 h. At a concentration 
above that threshold (4 µM), however, the penetration of T22-GWH1-GFP-H6 is 
extremely efficient. The amount of intracellular protein keeps increasing, without 
reaching any plateau at least during 24 h of exposure. During this experiment time, T22-
GWH1-GFP-H6 is majorly degraded at 1 µM, but only 60 % of the material is destroyed 
at 24 h in the endosomes at 4 µM (Figure 4B). This observation confirms again, the 
endosomal escape of the nanoparticles promoted by GWH1. Under this situation, most 
of T22-GWH1-GFP-H6 is found homogenously distributed by the cell cytoplasm, while 
the parental T22-GFP-H6 is majorly concentrated in a perinuclear region, as dissected 
by 3D confocal reconstructions (Figure 5A). The perinuclear localization of T22-GFP-H6 
fits with previous data that suggested a strong endosomal retention of this material [34]. 
The broadest intracellular distribution of T22-GWH1-GFP-H6 was confirmed by wide 2D 
confocal imaging of larger areas of cultured cells, at different magnifications (Figure 5B).  
 
 
 
Figure 5. Intracellular localization and fate of protein nanoparticles. A. 3D confocal 
reconstructions of cultured HeLa cells exposed to 4 µM of GWH1-empowered 
nanoparticles and the control T22-GFP-H6.  Blue label corresponds to the nucleus, red 
label to membranes and green label is the natural fluorescence of the nanoparticles. B. 
Broad confocal fields, at different magnifications, showing the intracellular localization of 
T22-GWH1-GFP-H6 homogenously distributed by the cell cytoplasm. All images were 
taken 24 h after exposure. 
 
 
 
Figure 6. Characterization of T22-GWH1-GFP-H6-Auristatin nanoconjugates. A. Mass 
spectrometry of T22-GWH1-GFP-H6-Auristatin (labelled as A) upon chemical 
conjugation. Eight peaks were identified corresponding to nanoparticles with seven to 
fourteen attached drug molecules. Flanking peaks are indicated with arrows, and also 
their molecular masses. The non-labelled peaks correspond to molecular masses of 
40.682, 41.601, 42.500, 43.413, 44.320 and 45.244 KDa respectively. At the bottom, the 
spectrum of drug-free nanoparticles. B. Hydrodynamic size distribution of T22-GWH1-
GFP-H6-A nanoconjugate compared to the drug-free nanoparticle. C. Reduction in cell 
viability of HeLa cells exposed to T22-GWH1-GFP-H6-A for 48 h, as compared to T22-
GFP-H6-A and T22-GWH1-GFP-H6. * indicates significant differences between T22-
GWH1-GFP-H6-A data and that of the other proteins.  
 
The high cell penetrability and improved endosomal escape conferred by the AMP to the 
protein nanoparticles, combined with the significant level of CXCR4 selectivity (Figure 3, 
4 and 5) prompted us to explore its potentiality as vehicles for targeted drug delivery, 
and therefore their potentiality for clinical applications. For that, we chemically coupled 
the antitumoral drug Auristatin to T22-GWH1-GFP-H6, and explored the ability of the 
nanoconjugate (T22-GWH1-GFP-H6-A) to deliver the drug in the cell cytoplasm. 
Auristatin is potent antimitotic peptide derived from the mollusc Dolabella auricularia, 
with applicability in targeted therapies in a spectrum of tumors [57]. The chemical 
conjugation rendered a narrow spectrum of nanoconjugates ranging from 7 to 14 drug 
molecules per nanoparticle, as determined by MALDI (Figure 6 A), and it slightly modified 
the volume and Zp of the materials (Figure 6B). When CXCR4+ cells were exposed to 
drug-loaded nanoparticles, a dramatic impact on cell viability was observed (Figure 6C). 
Importantly, the nanoparticle version lacking the AMP (T22-GFP-H6-A) was less efficient 
in promoting cell death (Figure 6C), confirming again the positive impact of this peptide 
in the release of the whole complex, including the drug, to the cytoplasm.   
 
  
Discussion 
Protein-based drugs are of high interest in molecular medicines as they can be produced 
among a spectrum of cell factories by simple recombinant DNA technologies [58]. In 
cancer therapies, modular approaches based on fusion protein engineering [41] allow 
recruiting, in single chain polypeptides, diverse functions required for efficient cell 
targeting, internalization and endosomal escape, that are encoded by proteins or protein 
domains [25, 59]. Self-assembling, that can be provided by short peptide stretches [20], 
allows the proteins being presented as regular oligomers within the nanoscale size, a 
presentation that enhances their tumoral accumulation by physical mechanisms linked 
to the EPR [8]. In a step further beyond the simple protein-drug association principles 
(on which Abraxane® is based [60]), nanostructured, cell targeted proteins can be ideal 
vehicles for drug targeting in cancer therapy in form of drug nanoconjugates [3]. We have 
here tested the combination of the AMP GWH1 [61], a potent membrane pore former, 
with T22 [34], a potent CXCR4 ligand, in protein-only CXCR4-targeted nanoparticles, 
regarding efficiency and specificity of CXCR4+ cell binding and penetrability. GWH1 is a 
synthetic AMP designed to show enhanced antimicrobial activity while reduced cell killing 
activity on normal eukaryotic cells, such as 3T3 fibroblasts [62] or erythrocytes (with low 
haemolytic activity) [63]. It also shows improved selectivity for surface binding and killing 
of cancer cells as compared to normal cells, because of similarly to bacteria, their 
membrane is enriched in anionic components [64]. GWH1 exerts its cytolytic activity by 
folding into an amphipathic helix upon selectively binding and insertion into the target 
membrane, leading to breakdown of the membrane structure, thus causing leakage of 
cell contents, finally resulting in cell death. Being used as a synthetic peptide alone, 
GWH1 is fully functional in form of fusion proteins [43], what opens the door to consider 
its inclusion in multifunctional constructs. The combination of pore-forming and cell-
targeting agents, despite their obvious interest in cancer therapies, has not been 
systematically explored.  
 
In this context, we have demonstrated here that the accommodation of GWH1 in longer 
modular polypeptides containing the cationic CXCR4 ligand T22 (Figure 1 A) does not 
affect neither the functionality of GWH1 nor the ability of the T22- and H6-empowered 
proteins to form regular nanoparticles (Figure 1A). Moreover, a clear membrane-
disrupting ability of T22-GWH1-GFP-H6 was shown over cancer cells with the expected 
threshold concentration (Figure 2), indicating the ability of GWH1 to create pores even 
in a nanoparticulated version. This fact can be obviously exploited to construct 
therapeutic protein materials based on functional recruitment, through simple fusion 
technologies. Interestingly, at sub-lethal concentrations, the GWH1 module enhances 
rapid and effective translocation of T22-GWH1-GFP-H6 nanoparticles from the endocytic 
vesicles into cytoplasm, when comparing with the parenteral T22-GFP-H6 (Figure 3). 
Interestingly, despite its observable endosomolytic activity, GWH1 does not promote 
release from vesicles into the cytoplasm except when administered at concentrations 
behaviour is compatible with molecular models currently proposed 
-helical antimicrobial sequences and the need 
of a threshold concentration for pore formation [53, 65, 66]. In this context, a punctuate 
fluorescence pattern was observed for internalized T22-GFP-H6 (Figure 5), indicating 
endosome permanence. In contrast, a different intracellular fluorescence pattern was 
shown by T22-GWH1-GFP-H6, characterized by a more homogeneous distribution of 
the material in the cytoplasm, consistent with the lysosomal release of a significant 
fraction of the recombinant cargo (Figure 5). 
 
Interestingly, membrane pore formation, although a fully unspecific and very efficient 
process, does not abort the specific CXCR4-dependent cell penetration mediated by T22. 
CXCR4 specificity is however reduced by the presence of GWH1 in the protein 
constructs from more than 90 % to 30 % (Figure 3C). This indicates that enhanced cell 
penetrability though pore formation cannot be gained simultaneously to a high cell 
specificity, as previously observed when exploring the fusogenic peptide HA2 from the 
influenza virus hemagglutinin [67]. However, since the in vivo tumor targeting of 
antibody-drug conjugates has determined to be around 1 % [1, 18], 30 % of receptor 
specificity appears as still good data. In this context, the protein nanoparticles generated 
here and empowered with GWH1 have been efficiently loaded with the antitumoral drug 
Auristatin by chemical conjugation (Figure 6). The presence of the AMP in the material 
dramatically improved the cytotoxicity of the drug in the nanoconjugate when exposed to 
cultured CXCR4+ cell (Figure 6 C), when compared to the use of the parental T22-GFP-
H6 as vehicle. These data, combined with the confocal microscopy imaging (Figure 5) 
and the experimental determining endosomal escape (Figure 3) demonstrate the 
endosomolytic properties of GWH1 when integrated, as a functional domain, in modular 
self-assembling proteins. Obviously, the clinical impact of pore formation combined with 
tumor cell targeting should be explored further. Since T22-based protein nanoconstructs 
have been recently shown extremely powerful for the precision delivery of chemical and 
protein antitumoral drugs [38-40, 42], the improvement of their intracellular trafficking 
properties, exploiting the functional versatility of protein materials, would be extremely 
desirable.   
 
Conclusion 
The obtained set of data stresses the strong value of membrane active peptides used as 
potential enhancers of drug penetrability and endosomal escape into target cells, when 
displayed in nanoscale supramolecular complexes. This has been proved here by the 
incorporation of GWH1 to a cell-targeted nanoscale protein vehicle through conventional 
protein engineering, generating a stable and functional nanomaterial. In addition, the 
presented results also point out that membrane pore formation does not preclude specific 
cell targeting mediated by a partner driver peptide, although the receptor specificity is 
reduced. In the current context of innovative drug design and the generation of smart 
nanoscale vehicles as delivery agents, the data presented in this study offer critical clues 
regarding the recruitment of appropriate functional agents based on recombinant 
proteins. The successful incorporation of membrane pore forming peptides into self-
assembling functional proteins offers a powerful approach to overcome one of the major 
bottlenecks in the endosomal delivery of protein materials, namely lysosomal 
degradation. 
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